Immune Reconstitution in the First Year of Potent Antiretroviral Therapy and Its Relationship to Virologic ResponseElizabeth Connick, Alan Landay, Michael M. Lederman et al.|The Journal of Infectious Diseases|2000Cited by 180
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, Brian L. Kotzin et al.|Nature Communications|2024Cited by 37
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosusChristie Fanton, Brian L. Kotzin, Richard Furie et al.|Journal of Translational Autoimmunity|2022Cited by 36
Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).Adi Diab, Brendan D. Curti, Mario Q. Marcondes et al.|Journal of Clinical Oncology|2019Cited by 26
OP0195 SELECTIVE EXPANSION OF REGULATORY T-CELLS IN HUMANS BY A NOVEL IL-2 CONJUGATE T-REG STIMULATOR, NKTR-358, BEING DEVELOPED FOR THE TREATMENT OF AUTOIMMUNE DISEASESChristie Fanton, Brian L. Kotzin, Suresh Siddhanti et al.|Annals of the Rheumatic Diseases|2019Cited by 5